# Brexafemme (ibrexafungerp) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ibrexafungerp

> The FDA approved Brexafemme (ibrexafungerp), sponsored by GSK plc (GSK), on Dec 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Brexafemme (ibrexafungerp) |
| Codes | MK-3118, SCY-078 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | Candidiasis, Invasive |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### June 1, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214900 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210601, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BREXAFEMME (IBREXAFUNGERP CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214900%22

### November 30, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214900 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20221130, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BREXAFEMME (IBREXAFUNGERP CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214900%22

### Dec 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-12, last confirmed 2025-05-15.
- SEC Form 10-K (accession 0000950170-25-038044): "In June 2021 and December 2022, we announced that the United States (U.S.) Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively." https://www.sec.gov/Archives/edgar/data/1178253/000095017025038044/scyx-20241231.htm
- SEC Form 10-K (accession 0000950170-25-038044): "In June 2021, the U.S. Food and Drug Administration ("FDA") approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis ("VVC"), also known as vaginal yeast infection, and in December 2022, the Company announced that the FDA approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis ("RVVC")." https://www.sec.gov/Archives/edgar/data/1178253/000095017025038044/scyx-20241231.htm
- SEC Form 10-Q (accession 0000950170-25-072548): "In June 2021, the U.S. Food and Drug Administration ("FDA") approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and in December 2022, the Company announced that the FDA approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis." https://www.sec.gov/Archives/edgar/data/1178253/000095017025072548/scyx-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-072548): "In June 2021 and December 2022, we announced that the United States (U.S.) Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively." https://www.sec.gov/Archives/edgar/data/1178253/000095017025072548/scyx-20250331.htm

### November 7, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Candidiasis, Invasive; Candidemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05178862 (A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Scynexis, Inc.; Results First Posted 2026-08-10." https://clinicaltrials.gov/study/NCT05178862

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ibrexafungerp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Brexafemme (ibrexafungerp) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ibrexafungerp

```bibtex
@misc{secapidev_pdufa_ibrexafungerp_20261116,
  title        = {Brexafemme (ibrexafungerp) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ibrexafungerp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ibrexafungerp_20261116","title":"Brexafemme (ibrexafungerp) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ibrexafungerp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
